S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic|
|ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib|
|ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer|
|Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference|
|Alkermes to Host Conference Call to Discuss Third Quarter 2014 Financial Results|
|Alkermes’ New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA|
|Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer|
|Alkermes’ Corporate Presentation to be Webcast at the Credit Suisse 2014 Healthcare Conference|
|Alkermes plc Reports Third Quarter 2014 Financial Results|
|Ignyta Announces Interim Data from RXDX-101 Phase I Clinical Trial at 2014 ESMO Congress|
Click above to view more mutual fund data and stats for alk - Alkane Resources Ltd.